Skip to content
Markets News
Stocks1 min read

China Clears HUTCHMED Drug for Two Autoimmune Blood Disorders

Makkler Newsroom
November 19, 2026 · Based on reporting by GlobeNewswire

The NMPA approved SYVIK for certain adults with chronic primary ITP and warm antibody autoimmune hemolytic anemia.

Key takeaways

  • China approved SYVIK for eligible adults with chronic primary ITP and warm antibody autoimmune hemolytic anemia.
  • In trials, durable response rates were 48.4% for ITP and 66% for wAIHA.

HUTCHMED said China’s National Medical Products Administration approved SYVIK for two autoimmune blood disorders: chronic primary immune thrombocytopenia (ITP) and warm antibody autoimmune hemolytic anemia (wAIHA).

The approvals cover adults with ITP who had an insufficient response to at least one prior therapy, and adults with wAIHA who had an insufficient response to corticosteroids. The company said SYVIK is the first novel Syk inhibitor approved in China.

In the ESLIM-01 ITP trial, the durable response rate was 48.4% with SYVIK and zero with placebo. In the ESLIM-02 wAIHA trial, durable response during weeks 5–24 was 66% with SYVIK, compared with 15% with placebo.

Topics
HCMSYVIK

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.